Starpharma Holdings

Starpharma Holdings Net Margin

The Net Profit Margin of Starpharma Holdings (SPL.AX) as of Oct 18, 2026 is -61.95 %. In the previous year, Net Profit Margin was -203.38 % — a change of -69.54% (higher).

Net Margin

-61.95 %

YoY

-69.54%

Last updated:

Net Profit Margin of Starpharma Holdings is 2026 -61.95 % . Net Profit Margin of Starpharma Holdings was 2025 -203.38 % . It decreases by -69.54% higher compared to the previous year.

For Starpharma Holdings, the net margin of -62.0% is up versus -345.0% a few years ago.

The Starpharma Holdings Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-524.04 AUD
Jan 1, 2020
-243.30 AUD
Jan 1, 2021
-1,097.44 AUD
Jan 1, 2022
-345.02 AUD
Jan 1, 2023
-532.09 AUD
Jan 1, 2024
-98.50 AUD
Jan 1, 2025
-203.38 AUD
Jan 1, 2026
-61.95 AUD
The Starpharma Holdings Net Margin history
YEARNet MarginYoY
-61.95 %-69.54%
-203.38 %+106.47%
-98.50 %-81.49%
-532.09 %+54.22%
-345.02 %-68.56%
-1,097.44 %+351.07%
-243.30 %-53.57%
-524.04 %+152.57%
-207.48 %-50.27%
-417.25 %-10.37%
-465.50 %-58.31%
-1,116.68 %-4.39%
-1,168.00 %+346.74%
-261.45 %+1,670.69%
-14.77 %+89.16%
-7.81 %+71.83%
-4.54 %+122.24%
-2.04 %-61.47%
-5.31 %-36.74%
-8.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Starpharma Holdings Stock analysis

What does Starpharma Holdings do? Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Starpharma Holdings stock

Net Profit Margin of Starpharma Holdings is -61.95 % in 2026.

Net Profit Margin of Starpharma Holdings changed from -203.38 % to -61.95 %, representing a -69.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Starpharma Holdings since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Starpharma Holdings with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Starpharma Holdings

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Starpharma Holdings